Do you know what situation your peers’ businesses are in, and what they’re working to? To find out just that, IQPC polled their network of pharmaceutical serialization professionals and got responses from representatives of over 20 companies.
The results? Most find data storage and management to be their biggest issue, citing ERP systems as some of their biggest investments in 2016 and going forward. It follows that over 50% of those we polled are either implementing their strategies in multiple sites or already done and thinking beyond compliance.
IQPC also asked about their biggest inhibitors, their current and future budgets, and their experience with international compliance. If you want to find out what your peers think about these topics, you can download the survey report, or meet them on-site at the Pharmaceutical Traceability Forum, May 23 – 25 in Philadelphia. Use the discount code PT_RXTRACE to get 20% off the standard price! Continue reading Sponsored: Tracking Serialization: 2016 Pharma Trace Market Trends
Ever since the 
According to the
Drug verification is at the heart of most pharma serialization regulations. It is the point at which someone in the supply chain or a patient uses the unique identifier on the drug package to determine that the drug is probably authentic, or definitely is not. We can tell a lot about the intent of a given serialization regulation by looking at the specific language that determines by whom and when a unique identifier must be verified.
Back in October the FDA announced the extended use of enforcement discretion to temporarily set aside the data exchange provisions of the Drug Supply Chain Security Act (DSCSA) for dispensers until March 1, 2016 (see “
Why is there such a wide gap between the actions of the UDI face of the FDA and the DSCSA face?
As serialization mandates sweep the world you would think that drug manufacturers and repackagers would just deploy one generic “serialization application” and simply turn it on for any drugs that requires it, and turn it off for any that do not. That’s probably what the legislatures and regulators who create the requirements think. RxTrace readers know it’s not nearly that easy.